초록 ▼

The present invention relates to a 3D bioprinted skin tissue model, a method for providing said model and the use of said model. The 3D bioprinted skin tissue model comprises at least one bioink A, at least one cell type A, at least one factor A, wherein the bioink A comprises at least one biopolyme

The present invention relates to a 3D bioprinted skin tissue model, a method for providing said model and the use of said model. The 3D bioprinted skin tissue model comprises at least one bioink A, at least one cell type A, at least one factor A, wherein the bioink A comprises at least one biopolymer, a thickener, at least one extra-cellular matrix or a decellularized matrix, and optionally a photo initiator and/or cellular additions, the at least one cell type A is an epidermal, dermal and/or hypodermal cell or cell line, and the at least one factor A is a growth factor, protein and/or molecule that stimulates altered or abnormal metabolism of cell type A.

대표청구항 ▼

1. A method of producing a skin tissue model in an automated manner, comprising the steps of: (a) providing at least one bioink A;(b) providing at least one cell type A;(c) providing at least one factor A;(d) mixing the components provided in steps (a)-(c), and optionally other components, in such p

1. A method of producing a skin tissue model in an automated manner, comprising the steps of: (a) providing at least one bioink A;(b) providing at least one cell type A;(c) providing at least one factor A;(d) mixing the components provided in steps (a)-(c), and optionally other components, in such proportions that allows printability for the mixture, and that provides a viable setting for the at least one cell type A;(e) bioprinting and/or dispensing the resulting mixture in an automated and reproducible manner, whereby a tissue model is formed, said tissue being characterized as a skin tissue;wherein the bioink A comprises at least one biopolymer, a thickener, at least one extra-cellular matrix or a decellularized matrix component, and optionally a photo initiator and/or cellular additions, such as sebocytes, glandular cells and/or follicle cells;wherein the thickener is a polysaccharide-based substance, such as nanocellulose, glucomannan, xanthan gum, gellan gum, diutan gum, welan gum or pullalun gum, or a protein-based substance, such as collagen or gelatin, that modulates the viscosity of the bioink A;the at least one cell type A is an epidermal, dermal and/or hypodermal cell or cell line of human and/or animal origin, said cells optionally being primary cells, immortalized and iPSC- or ESC-derived; andthe at least one factor A is a growth factor, such as fibroblast growth factor (FGF), epidermal growth factor (EGF), or vascular endothelial growth factor (VEGF), and/or small molecules, macro molecules, and/or proteins such as cytokines, hormones, lipids, carbohydrates or nucleic acids, that stimulates altered or abnormal metabolism of cell type A, said factor A being specific to epidermal, dermal and/or hypodermal cells and promoting cell proliferation, cellular repair, dermal vascularization, skin tissue maturation and/or other cellular stimuli such as motility and/or inhibition. 2. The method according to claim 1, wherein: the bioink A comprises (based on total weight of the bioink) 2-15% w/w, preferably 2-10% w/w, of at least one biopolymer, 0.5-3% w/w of thickener, 0.1-2% w/w of at least one extra-cellular matrix or a decellularized matrix component, and optionally 0.05-1% w/w of a photo initiator and/or 1×102-1×107 cellular additions per ml;the at least one cell type A is used in quantities of 1×103-10×107 cells per 1 mL Bioink and/or 1×103-10×105 cells per 1 cm2; and/orthe at least one factor A is used in quantities of 1×10−9-1×10−3 molar for growth factors, and 1×10−6-1×10−1 molar and/or 1-1000 mg/mL of other factors. 3. The method according to claim 1 or 2, wherein at least one additional cell type A, at least one additional bioink A, and at least one additional Factor A is provided, wherein the two or more bioinks are formulated so that bioink A supports one cell type A and the additional bioink(s) A support(s) a second or further cell type A. 4. The method according to any of claims 1-3, further comprising a step (f) of providing a cell suspension A, and applying said cell suspension A to the tissue formed in step (e), wherein the cell suspension A comprises cell relevant medium and/or materials synthetically derived or derived from bacteria, plants and/or animals, such as gelatine methacrylate, collagen, collagen methacrylate, alginate or cellulose, optionally a thickener,a cell type A,factors specific to cell type A which are proteins or molecules that will stimulate altered or abnormal metabolism of cell type A, said factor A being specific to epidermal, dermal and/or hypodermal cells and promoting cell proliferation, cellular repair, dermal vascularization, skin tissue maturation and/or other cellular stimuli such as motility and/or inhibition,optionally a photo initiator,optionally extracellular matrix proteins. 5. The method according to any of the claims 1-4, wherein the at least one biopolymer is chosen from the group comprising a nanocellulose or nanofibrillar cellulose, a gelatine, such as gelatine methacrylate, alginate, acacia gum, tara gum, glucomannan, pectin, locust bean gum, guar gum, carrageenan, and tragacanth. 6. The method according to any of claims 1-5, wherein the thickener is a polysaccharide-based substance, such as nanocellulose, glucomannan, xanthan gum, gellan gum, diutan gum, welan gum or pullalun gum, or a protein-based substance, such as collagen or gelatin; 7. The method according to any of claims 1-6, wherein the extra-cellular matrix or decellularized matrix components originate from a human or animal source, and may be chosen from the group comprising of glycosaminoglycans, collagens, elastin, proteoglycans, aggrecans, isolated laminins, glycol-amino-glycans such as hyaluronic acid and heparin, purified molecular proteins such as fibrinogen and fibrin and/or purified molecular proteins motifs such as the RGD-motif. 8. The method according to any of the claims 1-7, wherein the photo initiator is chosen from Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) or irgacure. 9. The method according to any of the claims 1-8, wherein the cellular addition is chosen from one or more of sebocytes, glandular cells, and/or follicle cells. 10. The method according to any of the claims 1-9, wherein the one or more cell type A is/are chosen from: (i) Epidermal cells such as keratinocytes, melanocytes, and/or epithelial cells originating from induced pluripotent stem cells, embryonic stem cells, other stem cells, primary cells, and cell lines of human and/or animal origin; or(ii) Dermal cells such as fibroblasts, endothelial cells, Schwann cells and/or dendritic cells originating from induced pluripotent stem cells, embryonic stem cells, other stem cells, primary cells, and cell lines of human and/or animal origin; or(iii) Hypodermal cells such as adipose cells, fibroblasts and/or macrophages originating from induced pluripotent stem cells, embryonic stem cells, other stem cells, primary cells, and cell lines of human and/or animal origin. 11. The method according to any of the claims 1-10, wherein the at least one cell type A originates from macro locations, such as a facial location, breast, belly, urethra, oesophagus and/or head, and/or from micro locations, such as papillary dermis or reticular dermis, of the body of healthy, diseased and/or defected human and/or animal sources. 12. The method according to any of the preceding claims, wherein step (e) is performed using an extrusion, syringe or ink-jet based bioprinting device. 13. The method according to any of the preceding claims, wherein the tissue is bioprinted or dispensed in a manner that produces two or more compartments and/or one or more cellular gradient(s) within the tissue. 14. The method according to claim 13, wherein the tissue is bioprinted or dispensed to form a hypodermal compartment, a dermal compartment and/or an epidermal compartment, and optionally wherein a cellular gradient is bioprinted or dispensed within one or more compartment(s). 15. The method according to any of the claims 13-14, wherein the two or more compartments and/or the cellular gradient(s) are bioprinted or deposited at the same occasion and/or at one or more later occasions. 16. The method according to any of the preceding claims, wherein the Factor A is chemically attached to, or trapped in, the at least one Bioink A and/or additional bioinks A, and/or incorporated with the at least one cell type A. 17. The method according to any of the preceding claims, wherein the produced skin tissue model is further subject to a culturing method wherein the skin tissue model is cultured (i) by being submerged in medium;(ii) in a flow device to mimic a vascular system; and/or(iii) at an air-liquid interface. 18. The method according to claim 17, wherein a combination of one or several culturing methods is used for the same skin tissue model, either simultaneously and/or sequentially. 19. A 3D bioprinted skin tissue model, comprising i. at least one bioink Aii. at least one cell type Aiii. at least one factor Awherein the bioink A comprises at least one biopolymer, a thickener, at least one extra-cellular matrix or a decellularized matrix, and optionally a photo initiator and/or cellular additions;the at least one cell type A is an epidermal, dermal and/or hypodermal cell or cell line of human and/or animal origin, said cells optionally being primary cells, immortalized and iPSC- or ESC-derived;wherein the thickener is a polysaccharide-based substance, such as nanocellulose, glucomannan, xanthan gum, gellan gum, diutan gum, welan gum or pullalun gum, or a protein-based substance, such as collagen or gelatin; andthe at least one factor A is a growth factor, such as fibroblast growth factor (FGF), epidermal growth factor (EGF), or vascular endothelial growth factor (VEGF), and/or small molecules, macro molecules, and/or proteins such as cytokines, hormones, lipids, carbohydrates or nucleic acids that stimulates altered or abnormal metabolism of cell type A, said factor A being specific to epidermal, dermal and/or hypodermal cells and promoting cell proliferation, cellular repair, dermal vascularization, skin tissue maturation and/or other cellular stimuli such as motility and/or inhibition. 20. The 3D bioprinted skin tissue model according to claim 19, wherein: the bioink A comprises (based on total weight of the bioink) 2-15% w/w, preferably 2-10% w/w, of at least one biopolymer, 0.5-3% w/w of thickener, 0.1-2% w/w of at least one extra-cellular matrix or a decellularized matrix component, and optionally 0.05-1% w/w of a photo initiator and/or 1×102-1×107 cellular additions per ml;the at least one cell type A is used in quantities of 1×103-10×107 cells per 1 mL Bioink and/or 1×103-10×105 cells per 1 cm2; and/orthe at least one factor A is used in quantities of 1×10−9-1×10−3 molar for growth factors, and 1×10−6-1×10−1 molar and/or 1-1000 mg/mL of other factors. 21. The 3D bioprinted skin tissue model according to any of the claims 19-20, wherein the at least one biopolymer is chosen from a nanocellulose, or nanofibrillar cellulose, or a gelatine, such as gelatine methacrylate. 22. The 3D bioprinted skin tissue model according to any of the claims 19-21, further comprising an additional cell suspension A, said cell suspension A comprises of cell relevant medium and/or materials synthetically derived or derived from bacteria, plants and/or animals, such as gelatine methacrylate, collagen, collagen methacrylate, alginate or cellulose, optionally a thickener, a cell type A, factors specific to cell type A which are proteins or molecules that will stimulate altered or abnormal metabolism of cell type A, said factor A being specific to epidermal, dermal and/or hypodermal cells and promoting cell proliferation, cellular repair, dermal vascularization, skin tissue maturation and/or other cellular stimuli such as motility and/or inhibition, optionally a photo initiator, optionally extracellular matrix proteins. 23. The 3D bioprinted skin tissue model according to any of the claims 19-22, wherein the one or more cell type A is/are chosen from (i) Epidermal cells such as keratinocytes, melanocytes, and/or epithelial cells originating from induced pluripotent stem cells, embryonic stem cells, other stem cells, primary cells, and cell lines of human and/or animal origin; or(ii) Dermal cells such as fibroblasts, endothelial cells, Schwann cells and/or dendritic cells originating from induced pluripotent stem cells, embryonic stem cells, other stem cells, primary cells, and cell lines of human and/or animal origin; or(iii) Hypodermal cells such as adipose cells, fibroblasts and/or macrophages originating from induced pluripotent stem cells, embryonic stem cells, other stem cells, primary cells, and cell lines of human and/or animal origin. 24. The 3D bioprinted skin tissue model according to any of the claims 19-23, wherein the model comprises at least one compartment, representing a hypodermal, a dermal and/or an epidermal compartment. 25. The 3D bioprinted skin tissue model according to any of the claims 19-24, wherein the model comprises two or more compartments representing a biological gradient corresponding to a hypodermal, a dermal and/or an epidermal compartment; and optionally comprising a biological gradient within one or more of said compartments. 26. Use of the 3D bioprinted skin tissue model according to any of the claims 19-25, in one or more of: (i) Developmental biology in order to gain understanding of cellular activities within a 3D environment such as cellular distribution, migration, proliferation, matrix production, interactions with other cells and the surrounding environment, etc.; and/or(ii) Compound testing for cosmetic and skin care product evaluation, toxicity studies, irritant studies, allergen testing, metabolism studies, tissue and/or cellular rejuvenation investigations, photosensitivity testing, drug and/or molecular compound absorption testing, cellular differentiation/maturation, spheroid differentiation/maturation, organoid differentiation/maturation, etc.; and/or(iii) Tissue regeneration and rejuvenation applications such as tissue remodelling, cellular proliferation, cellular metabolism, cellular differentiation/maturation, cell-cell interaction, cell-matrix interaction, cellular crosstalk/signalling, vascularization, etc.; and/or(iv) Pharmaceutical applications for drug discovery, target validation, allergen studies, toxicity studies, metabolism studies, cellular differentiation/maturation, spheroid differentiation/maturation, organoid differentiation/maturation, etc.; and/or(v) Medical device evaluation and development, toxicity studies, allergen studies etc. for devices in contact with internal and/or external skin linings; and/or(vi) Stem cell research with focus on cellular differentiation and maturation as dispersed cells, spheroids, organoids, etc. 27. Use of the 3D bioprinted skin tissue model according to claim 26 in applications relating to both internal and external skin linings such as the skin, oesophagus and urethra.